Blog

After 20 years, this new chapter integrates 12 acquisitions to deliver data-driven, tech-enabled health marketing and communications solutions, accelerated by the COVID-19 pandemic

San Francisco (March 10, 2021) – W2O, the healthcare marketing and communications powerhouse founded 20 years ago by Jim Weiss, announced today that it has transformed into a new kind of healthcare company named Real Chemistry. Healthcare is undergoing a radical transformation that has only accelerated since the outbreak of COVID-19. Real Chemistry is designed to address the forces driving this disruption, including digitization, consumerization and value-based care. Real Chemistry is a unified “health innovation company” that combines award-winning expert services in digital marketing, creative and communications with clinical trial, health economics and outcomes, and value, pricing and access advisory expertise. All of these expert services are powered by proprietary data and technology that deliver comprehensive health solutions for the challenges facing healthcare companies today.

“For 20 years, our work and our passion have been about making the world a healthier place for all,” said Jim Weiss, CEO and Founder of Real Chemistry. “Innovation in healthcare has never been faster or more important. The pandemic has shown us that communications plays a more vital role than ever to ensure life-changing healthcare solutions get to the right person at the right time and place. That is why this moment is about so much more than a new name or approach. It’s about how our ethos of action, our two decades of intentional evolution, and our drive for constant improvement helped us create what we see as the real chemistry between people and the brands born to change their lives.”

Today’s announcement comes as changes in healthcare continue to rapidly accelerate – with patients more in control than ever before. Information and services are increasingly delivered via intelligent technologies, with the goal of tailoring solutions to each individual at any place, time or context – from clinical trial design to treatment and ongoing health communication. In the years ahead, the health ecosystem will continue to rapidly evolve, driven by health and digital literacy, agency and the self-determination of care.

According to research from McKinsey & Company,[1] pharmaceutical executives today are 28% more likely to cite innovation as their #1 or #2 priority than before the pandemic, which is in stark contrast to significant declines in this measure for every other industry. The same study found that only 21% of executives feel equipped to address new growth and innovation demands, while 66% believe this is the most challenging moment in their entire career. These findings, and similar research, have reinforced that there is a clear need for new models and approaches, such as what Real Chemistry is striving to deliver. Today’s health ecosystem is striving to address demands to be increasingly patient-centric, outcomes-driven and digitally connected. Physicians and patients are increasingly digital natives and prefer digital channels of connection. Savvier patients and consumers of products and services are increasingly demanding seamless and tailored engagement across channels. Providers increasingly express preference for quick, personalized, consumable content that can be easily shared with staff and patients in a digital and shareable format. Research has shown that, on average, healthcare professionals report having worse experiences with remote engagement, with many contributing factors, including inadequate content that is not adapted for virtual interaction.

Real Chemistry invested early and often in data, digital and tech-enablement and has more than 400 analysts, digital experts and data scientists. Data and technology are core to the vision, but Real Chemistry’s greatest value rests in its people and culture. The company’s core belief is that the way to real, transformative change is through the alchemy of talents, disciplines and technologies to create entirely new, more insightful ways to solve problems.

“We’re driven to help our clients move faster and with more precision and efficiency. Recent events make clear the importance of value-based and outcomes-driven engagement, designed to connect the right patients to the right treatment at the right time,” added Jennifer Gottlieb, Global President of Real Chemistry. “Real Chemistry can do this for clinical trials, new product launches and commercialization opportunities – all focused on successfully navigating product lifecycles to ultimately improve health outcomes, in partnership with our clients.”

All executive leadership, corporate functions (e.g., operations, finance and human resources) and key shared services (e.g., data, analytics, technology, branding, media, activation and performance marketing) will sit across the Real Chemistry platform. Real Chemistry Health Technologies will house a portfolio of proprietary technology products, including Swoop and IPM.ai, as well as the Symplur Suite of social listening, analytics and engagement tools. Real Chemistry’s Hū capability will lead innovation and improvement in the clinical trial experience.  Real Chemistry’s key expert service brands include W2O, which is focused on integrated communications; 21GRAMS, which continues to lead in advertising; Discern, which delivers expert value and access consulting; and starpower, a team of cultural strategists leading the “Hollywood meets healthcare” movement.

About Real Chemistry

Real Chemistry is a global health innovation company with an alchemic mix of 1,600 people and hundreds of clients and partners working from bench to bedside, making the world a healthier place. Purpose-built by Jim Weiss to address modern healthcare challenges, Real Chemistry is the culmination of 20 years of intentional, fiercely independent, sustained growth. With offices across the United States and Europe, Real Chemistry believes that the way to real, transformative change is through the uncommon combination of talents, disciplines and technologies.

Real Chemistry’s proprietary technology products include Swoop, IPM.ai and the Symplur Suite of social listening, analytics and engagement tools, all housed within Real Chemistry Health Technologies. Tools focused on clinical trial engagement live within Hū, and expert service brands include W2O (integrated communications), 21GRAMS (advertising and medical), Discern (value-based care consulting), and starpower (influencer and entertainment marketing). Integrated intelligence, media and marketing are all within Real Chemistry’s Integrated Marketing and Intelligence Services (IMIS).

For more information, please visit www.realchemistry.com and connect with us on Twitter and LinkedIn.

[1] McKinsey & Company. “Innovation in a Crisis: Why It Is More Critical Than Ever.” June 2020.

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

# # #

Tags:

San Francisco, February 11, 2021 –  Global health innovation leader W2O announced today that Stephanie Garcia has joined the company as Chief People Officer to integrate, empower and connect the company’s 1,600 and growing workforce.

Garcia comes to W2O with 24 years of exceptional HR and business operational experience at a pivotal time in the firm’s evolution. Previously, she was Senior Vice President, People and Civic Labs, at Postmates, where she had responsibility for the entire People function. Garcia led the Postmates workforce as it scaled from 800 to 1,400+ employees and drove the company’s people efforts throughout the pandemic and leading up to its recent acquisition by Uber. Before that, Garcia led global HR and business performance at PayPal and Salesforce. She also held HR leadership roles at Life Technologies Corporation, a leader in biotech solutions, prior to its acquisition by Thermo Fisher Scientific.

“I’m excited to join W2O at this point in their trajectory,” said Garcia. “The team is writing a dynamic story in the healthcare technology industry – for clients, patients, communities and W2O’s dedicated people. It’s not often you’re able to find a company that has purpose, people and business strength, together in one incredibly authentic package.”

Garcia’s extensive track record at world-class technology companies spans across all HR capabilities, including talent, culture and team development, diversity, equity and inclusion, organizational design, management coaching and performance metrics. She has excelled in working with high-tech, product-driven teams and recruiting technical talent in a competitive environment. She was integral at PayPal and Salesforce during some of their most intense growth years.

W2O began a partnership with leading private equity firm New Mountain Capital in June, 2019. Since then, W2O has made nine acquisitions and hired nearly 1,000 people to become a go-to partner of choice to help clients accelerate clinical trials, achieve commercial success, and navigate and engage their key stakeholders in an increasingly digital, data-driven, tech-enabled post-COVID-19 reality. W2O achieved $360 million in revenue in 2020, a 60% increase over 2019, and expects to grow again significantly in 2021.

“Stephanie brings incredible energy and a refreshing perspective that will help us achieve our ambitious vision for the future,” said Jim Weiss, Founder and CEO of W2O. “I’ve always said that our motivated, talented people have been the key to our success and that our mission of making the world a healthier place begins with us. Her strategic business skills and understanding of the technology industry will ensure the continued high performance, synergy and diversity of our workforce.”

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,600 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com and connect with us on Twitter, LinkedIn and Facebook

# # #

 

Contact:

W2O Media Relations

Danya Proud

dproud@w2ogroup.com

312-919-6239

Tags:

San Francisco, January 22, 2021 – Global health innovation leader W2O today announced it has created three new positions to lead W2O’s continued growth and transformation across the healthcare spectrum.

“Expanding our performance marketing engine with Jo Ann Saitta, Marcos Mendell and Larry Mickelberg complements the robust capabilities W2O has to guide clients in the midst of digital transformation,” said David Magrini, President, CRM and Marketing Solutions,  W2O. “These leaders bring the right mix of digital, technology and marketing expertise to help our clients navigate today’s – and the future – environment.”

This new leadership provides the perfect complement to W2O’s recently formed Health Technology Business. W2O’s unmatched combination of data, technology and people will further power digital transformation across the clinical and commercial ecosystem.

“This expanded digital leadership, combined with the power of W2O’s data and analytics, gives us precision targeting and segmentation for modern healthcare advertising,” said Bob Blink, Group President, 21GRAMS. “Our mantra is using insights to evolve healthcare marketing and continue to be first at what’s next.”

Jo Ann Saitta – Global Chief Digital Officer

Saitta will lead the development of W2O’s omnichannel performance marketing capabilities, with a focus on activating audience insights through technology and data strategies. Named as one of “16 Women Changing Healthcare” by MM&M and CIO of the Year by the NJ Technology Council, Saitta is also a member of the Google Health Marketing and Advertising Advisory Board.

Saitta was most recently the global Chief Digital Officer at Omnicom Health Group, where she set the strategic direction for the technology center of excellence, including operational excellence, product development, and customer satisfaction. In this role, Saitta forged the first digital health partnerships with technology leaders, including IBM Watson, Google and Apple, and brought multiple products to market. Prior to Omnicom, she served as CIO of a contract commercialization organization and held various technology roles at IBM.

Marcos Mendell – Executive Vice President, Health Platform Innovation

Mendell will create and lead digital capabilities and solutions at-scale through custom, adtech and martech platforms. These capabilities will leverage data, analytics and media to drive outcomes for W2O customers.

Prior to joining W2O, Mendell was Global Lead, Commercial and Omnichannel Solutions at Syneos Health, where he defined and implemented its omnichannel product model. He also developed and delivered technology product solutions to better engage customers for Contract

Field Sales, Sales Operations, Contact Centers, Applied Data Science, Advertising and Consulting. Before Syneos Health, Mendell worked at Pfizer for nearly 11 years, where his last role was U.S. Business Intelligence Lead. He spent his early career serving in progressive account and project management roles at Agency.com, Organic and Wunderman Thompson.

Larry Mickelberg – Group President, Technology and Engagement

Mickelberg will develop innovative approaches to digitize the commercial vision and strategy for W2O’s creative business, 21GRAMS. He will direct global digital business that creates personalized health experiences through integrated engagement channels, tools and techniques. Mickelberg is a C-suite advisor and recognized thought leader on digital transformation in the future of health and wellness. He spoke recently at HIMMS, Dreamforce and Ad Club and was recognized by MM&M’s “Top 50 Health Influencer” power list from 2017 to 2019.

Prior to joining W2O, Mickelberg was a Managing Director at Deloitte Digital, where he was the U.S. practice leader for advertising and experience for life sciences clients. Before Deloitte, he was a global Partner and Chief Digital Officer at Havas Health. Earlier, he was on the founding executive team at Digitas Health as EVP of strategy and development.

About W2O 

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved 19 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com and follow W2O on Twitter, LinkedIn and Facebook. 

# # #

Contact:

W2O Media Relations

Danya Proud

dproud@w2ogroup.com

312-919-6239

Tags:

2020 Revenue Tops $350 Million for W2O, With Accelerated Momentum into 2021

San Francisco (January 7, 2021) – Global health innovation leader W2O today announced it has acquired tech-enabled companies Swoop and IPM.ai, further accelerating what is expected to be its 20th consecutive year of double-digit revenue growth.

“The next frontier for the healthcare industry is using value-based and outcomes-driven messaging to connect the right patients to the right treatment at the right time,” said Jim Weiss, Founder and CEO of W2O. “In the increasingly digital post-pandemic era, we need to help our clients move faster and with more precision and efficiency to conduct clinical trials, launch new products, maximize peak revenue opportunities, and successfully navigate product lifecycles. The acquisition of Swoop and IPM.ai enables this game-changing approach – with the goal of improving healthcare from bench to bedside.”

Swoop and IPM.ai are pioneers in using machine learning, artificial intelligence, and real-world data to solve big challenges in healthcare. Swoop creates precise patient audiences, improving targeting of healthcare engagement and empowering patients to become active participants in their treatment journey. IPM.ai uncovers the ideal patient, enabling accelerated research, development, and commercialization of life-saving therapies in under-defined patient populations.

“Joining W2O brings Swoop and IPM.ai access to additional resources, health care expertise and opportunities to fuel our already impressive growth, as we help life sciences companies uncover, activate and ultimately engage their ideal patient populations and health networks,” said Ron Elwell, Founder and CEO of Swoop and IPM.ai. “Our existing leadership team, technologists, data scientists, life sciences experts and digital marketing professionals will continue to serve our customers, while expanding our team and reach over time.”

The Swoop and IPM.ai acquisition is the ninth for W2O since the company announced its partnership with New Mountain Capital in 2019. W2O achieved more than $350 million in revenue in 2020, an increase of 50% from the prior year.

“Our newly established Health Technology Business combines W2O’s robust data and analytics software with the Symplur, Swoop and IPM.ai tech and data assets. For customers, this will provide a powerful combination of tech-enabled strategic services along with DaaS and SaaS solutions, enabling digital transformation across the clinical and commercial ecosystem,” said Adam Cossman, Group President/Managing Partner of W2O’s Health Technology Business. “We have evolved our business and made big bets on tech-enablement over the past few years and this is another milestone in our transformation to becoming a healthcare innovation company. The Swoop and IPM.ai acquisition catapults us further into this space, adding new solutions to meet the accelerated, real-time changes happening in health care.”

“New Mountain has a long-standing focus on improving healthcare through the application of data and technology,” said Matt Holt, Managing Director and President of Private Equity at New Mountain. “We are excited to continue to invest behind the W2O team to achieve this vision and support their accelerated growth plan.”

“We are working closely with W2O to reimagine an industry that is ripe for transformation, as life sciences companies look to digitize how they go-to-market, conduct clinical trials, and engage with patients, clinicians and decision makers,” added Brian Murphy, Director at New Mountain. “The combination of Swoop and IPM.ai with our existing Health Technology Business will significantly supercharge our efforts in this space and deliver innovative new solutions for clients.” 

About Swoop

Swoop empowers the world’s leading pharmaceutical brands to better-educate patients about disease states and the therapies that could remedy their conditions, as well as enable them to become active participants in their treatment journey. Swoop’s HIPAA-certified and NAI-accredited system of engagement uncovers unique target audiences for precisely activating patient populations and their healthcare ecosystems through cross-channel marketing strategies. By utilizing artificial intelligence and machine learning in conjunction with a real-world evidence, social determinants of health and outcomes research data universe of over 300 million de-identified patients and 65 billion anonymous consumer interactions, Swoop’s patient segments are superior in audience quality, lead to optimal conversion, and drive increased Rx lift.

About IPM.ai

IPM.ai is an Insights as a Service (IaaS) provider that empowers the world’s leading life sciences companies to better understand and improve the lives of patients through the development and commercialization of precision medicine for specialty and rare diseases. IPM.ai’s system of insight streamlines market assessment, patient finding, treatment journey mapping, healthcare provider discovery, key opinion leader identification and brand activation by utilizing granular-level longitudinal analytics, artificial intelligence, and machine learning in conjunction with real-world evidence, social determinants of health, and an outcomes research data universe of over 300 million de-identified patients.

About W2O 

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid, and doing the right thing, W2O has achieved 19 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place. Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future. For more information, please visit www.w2ogroup.com. or follow us on Twitter, LinkedIn and Facebook.

# # #

Tags:

W2O Uncovers Link Between Doctors Providing Telehealth Services and Their Twitter Presence

San Francisco (December 17, 2020) – Patient-physician engagement using Twitter has nearly doubled since the start of the pandemic and doctors are increasingly engaging with patients on a wide range of topics, including impact of COVID-19 on regular care, racial inequalities in health care, and the safety and efficacy of vaccines. These key conclusions as well as other pivotal trends are part of a new report by W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector. 

Even with offices closed, the doctor was always in thanks to Twitter. W2O detected a stunning 93% increase in patient engagement with physician content on the platform since the pandemic began in March 2020. The initial increase was driven almost exclusively by COVID-19-related topics, but evolved to a broader range of health-related topics. Looking deeper at these more digitally savvy doctors, research found that doctors who engaged with patients and other doctors on Twitter had the highest number of telehealth claims in the first six months after the pandemic began, with increases ranging from 27% to 55%. These results show that many of the physicians who are successful at leveraging Twitter as a communications platform are the same ones who have successfully adopted digital technologies to provide care to patients despite the disruptions of COVID-19.

“COVID-19 has accelerated the unstoppable train that is people adopting technology to understand, manage and improve their health,” said Seth Duncan, W2O’s Chief Data Officer. “This new report demonstrates that social media is an integral part of how medical information is shared between healthcare professionals and consumers and is an essential part of the health data ecosystem.”

The research was conducted using Symplur, a W2O technology platform. Using Symplur’s proprietary data taxonomy and Symplur Signals, the first social listening product designed exclusively for healthcare, W2O explored how the pandemic has impacted physicians’ connections with patients and their peers on Twitter, and the resulting healthcare delivery changes. W2O chose to look at online conversation on Twitter exclusively as it is one of the best representations of the intersection of relevant conversation among patients, caretakers, healthcare professionals (HCPs) and public health officials.

“Twitter has always been the go-to platform for HCPs who want to share information quickly and effectively,” said Lisa Bookwalter, Twitter’s Director, Health Client Solutions. “However, the realities of COVID have accelerated this trend in ways we could not have imagined. Twitter is now an integral part of how HCPs are able to conduct business, share research, communicate with patients, or access the latest public health information from across the globe. This opens up a new channel to engage with this hard-to-reach audience.” 

According to W2O’s research, the sharing of medical information by doctors increased by 26% year-over-year, resulting in greater access for consumers to scientific information. The research suggests an emerging tide of physicians who are connecting patients directly with medical literature, often in a way that explains or contextualizes that literature. This trend has important implications for the future of healthcare. 

The full report can be found here

About W2O 

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved 18 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place. 

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future. Symplur Signals is the only healthcare-centric social platform built by industry for industry that uses Machine Learning and Artificial Intelligence to monitor and analyze the conversations of over 1 million healthcare social profiles daily.

For more information, please visit www.w2ogroup.com.

Follow W2O on TwitterLinkedIn, and Facebook.

Follow Symplur on TwitterLinkedIn and Facebook.

# # #

Contact: 

W2O Media Relations

Danya Proud

dproud@w2ogroup.com

312-919-6239

 

Tags:

Senior Leadership Appointments, Promotions and New CEO Advisory Board Member

Drive Comprehensive DE&I Strategy

 San Francisco, December 10, 2020 W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, today announced its Diversity, Equity & Inclusion (DE&I) department and practice. This  dedicated team was established to anchor DE&I into every aspect of the firm’s business and counsel clients on the most pressing DE&I issues. These experienced leaders will drive the company’s strategy, accountability and transparency in achieving DE&I goals.

“Our mission is to make the world a healthier place, and we know the world is healthiest when it’s diverse and equitable,” said Jennifer Gottlieb, Global President of W2O. “Establishing this robust department and practice reinforces our commitment to embed DE&I into every fiber of our company. More than hiring a consultant or single leader, our holistic approach serves all key stakeholders – our people, clients and communities – and is the foundation on which we will drive change, continue to hire and retain diverse talent, and ultimately hold ourselves accountable.”

Leading the Charge

Marcia Windross has been appointed Head of DE&I, bringing more than 20 years of global DE&I experience to her role at W2O. She will provide strategic leadership for continued transformation, and drive DE&I accountability, engagement and culture internally. Previously, Windross was a Senior Leader of DE&I at Interpublic Group, where she partnered with key stakeholders and led its efforts across 100+ agencies and 54,000 employees. In that role, she championed efforts to get women and people of color into the C-suite, led a diverse talent pipeline program, built a mentoring culture, global business resource groups, and external partnerships and led the annual DE&I survey.

Newly promoted long-time W2O executive Abby Hayes will build upon the strong foundation she has already laid with clients in this area in her new role as Practice Leader, DE&I Engagement. Hayes will develop data-driven, tech-enabled solutions that turn insights into action on the world’s most pressing issues, including COVID-19 health inequities, and racial and socioeconomic health disparities. She will continue to provide culturally competent, purpose-driven client counsel, uplevel W2O thought leadership, and infuse DE&I insights to inform short- and longer-term client strategy and activations.

Both Windross and Hayes will report to Gottlieb.

W2O has hired Karla Talley as Director, DE&I. Talley led DE&I efforts at Kraft, Digitas NA and the University of Michigan, where she built strong partnerships with talent acquisition teams, campus programs and faculty, and the industry at large. In her new role, she will focus on developing holistic DE&I programming and infusing it into W2O’s learning and development strategy.

Toni Pringley joins W2O as Manager, DE&I. Previously at OMG, her team led DE&I across 12 agencies with 4,500 employees as part of Omnicom’s overall Open Leadership DE&I Network. Her experience includes working with Business Resource Groups and partnering with talent acquisition to drive recruitment and retention through career fairs, educational content and new hire training. Pringley will help bring W2O’s DE&I strategy to life by driving action in the areas of recruiting, Business Resource Groups and internal engagement.

Both will report to Windross.

W2O has also added Mary Stutts to its CEO Advisory Board to ensure DE&I accountability at the highest levels. Stutts is a seasoned inclusion, diversity and corporate branding leader in biotechnology, healthcare, consumer, technology and media industries including Genentech, Bristol Myers Squib, Bayer, Comcast NBCUniversal, UnitedHealth Group and Kaiser Permanente. At Stanford Healthcare Stutts established the first Inclusion, Diversity & Health Equity program and remains an advisor for Stanford’s health equity program. Additionally, Stutts is the founder of The Center for Excellence in Life (TCEL), a non-profit dedicated to empowering youth and professionals through life skills development, mentoring, career coaching, and social and business etiquette training.

“Healthcare transformation is happening faster than ever, and inclusion and access is the future,” said Jim Weiss, Founder and CEO of W2O. “This year, we tackled critical areas of DE&I by providing tangible data, insights and pro-bono communications support to partners including the Black Coalition Against COVID and TCEL. To improve our efforts, we listened and engaged our internal Business Resource Groups to have the tough, but candid, conversations and used their insights to guide and inform our holistic strategy. Additionally, we conducted an independent, third-party culture audit. Collectively, these actions are making the world a healthier place – for W2O, our clients and our communities.”

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com and connect with us on Twitter, LinkedIn and Facebook

# # #

Contact:

W2O Media Relations

Danya Proud

dproud@w2ogroup.com

312-919-6239

Tags:

Targeted approach helps users convert healthcare data and insights into action

Join inaugural Symplur Moves webinar on Tuesday, Nov. 10 at 12:30 p.m. ET

San Francisco, October 29, 2020 – W2O today announced two new products available through Symplur, its social media analytics platform dedicated exclusively to the healthcare industry. These products provide understanding of what physicians see, do, and say, making insights easily available to life science companies to improve engagement with physicians.

The waiting room has gone virtual. The COVID-19 pandemic has forced interactions between patients and healthcare providers (HCPs) from in-person to online. Since March, on Twitter alone, Symplur has seen a 93% increase in online engagement around shared content and conversations between consumers and physicians.

“The power of this insight is clear. During COVID-19, for example, we saw conversations among cardiologists significantly increase as observational evidence showed that SARS-CoV-2 not only affects the respiratory tract but can cause significant damage to the heart,” said Audun Utengen, Co-Founder of Symplur. “This type of real-time insight helps providers advance care and life science companies adapt therapies, all for the benefit of patients. Over the past decade, we have evolved the Symplur platform to provide robust, real-time learnings around how to listen, and what to listen for, relative to global healthcare conversations.”

Building upon the success of Symplur Signals, Symplur Spotlight and Spotlight Engage are both aimed at physician behavioral insights, serving as a catalyst to help inform points of view and define commercial strategies. These two new products empower Symplur customers with the data and insights needed to make enhanced connections in an increasingly cluttered environment, further helping life science companies translate insights into action – in real time.

“The pandemic has further fast-tracked the adoption of healthcare technology, which means healthcare conversations move at light speed,” said Adam Cossman, Group President/Managing Partner Technology Products and Solutions, W2O. “Life science companies need access to the right information at the right time to help the right patients. Symplur stitches data together from multiple dispersed data sets, creating an integrated view – and has made it easy to access through user-friendly analytics. This puts important, actionable healthcare data where it can have the greatest impact.”

Symplur Spotlight is an integrated technology and analytics solution that stitches together a comprehensive set of data, including prescribing and diagnosis trends, social media data from Symplur’s Healthcare Social Graph®, clinical trials, publications and the Sunshine Act. These are used to establish data-rich physician profiles that can be ranked with a variable weighting methodology using Spotlight’s proprietary algorithms, which are ideal for key opinion leader (KOL) and key opinion influencer (KOI) mapping efforts and target list development.

Symplur Engage is designed to turn social media insights into meaningful healthcare field engagement. Intended for field-based reps and medical science liaisons (MSLs), Symplur Engage delivers social media dashboards directly into leading industry platforms such as Veeva and Salesforce. These dashboards can be created by customers directly and deployed easily to field staff, providing valuable insights to improve physician engagement.

Learn More about Symplur’s Offerings

Please join the inaugural Symplur Moves webinar series on Tuesday, November 10, at 12:30 p.m. Eastern Time. Participants will be introduced to Symplur, learn about its capabilities, and hear tips and tricks that get people to listen and move people to act.

About Symplur

Acquired by W2O in April of 2020, Symplur creates products purpose-built for healthcare to make the move from insight to action as simple as possible. As social media has increasingly broadened its role in healthcare communication, conversations, ideas and leaders on social platforms have become meaningful data sources. Symplur exists to connect the dots between social and real-world data (RWD) and identify actionable insights for those serving the healthcare community.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com

Follow W2O on Twitter

Follow W2O on LinkedIn

Follow W2O on Facebook

# # #

Tags:

Pioneer in Hollywood Meets Healthcare to Match up Talent, Clients and Causes to Make the World a Healthier Place

San Francisco and New York, October 5, 2020 W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions, today announced the acquisition of entertainment and influencer marketing agency starpower. The agency, which has offices in New York and Los Angeles, was founded in 2007 by lifelong friends Matthew Lalin and Jared Weiss. Since then, starpower has been a leader in influencer, celebrity and entertainment marketing, creating innovative and unique partnerships backed by data-driven social strategies for brands across health and wellness, consumer, lifestyle, entertainment and sport.

A pioneer in “Hollywood meets Healthcare,” starpower has engaged high-profile talent to infuse pop culture and relevance into public education, marketing and media campaigns. The team has worked with talent such as Serena Williams, Howie Mandel and Chrissy Teigen along with networks of micro-influencers for targeted social campaigns. Notable work leveraging starpower’s influencer marketing expertise includes its partnership with Novo Nordisk and Anthony Anderson on the award-winning “Get Real About Diabetes” campaign, and “Bayer Presents the Luke Bryan Farm Tour”, which benefited Feeding America.

“Consumer empowerment is more important than ever as the COVID-19 pandemic accelerates digitization and a sea change in the way people manage their life and health,” said Jennifer Gottlieb, Global President of W2O. “There couldn’t be a more important time for us to join forces with starpower as we continue to realize our vision to be the ‘first at what’s next’ in health. With telemedicine finally coming of age, consumers embracing the appification of healthcare, and a renewed focus on wellness, it’s clear that influencers are more critical than ever before.”

“The explosive growth of digital and social channels coupled with the true maturation of influencer marketing as a discipline has opened the door to a whole new world of entertainment and media possibilities for brands in all sectors,” said Weiss. “Building off our heritage in the consumer, lifestyle and spirits industries, we have been working with health and wellness brands for a number of years to tell compelling stories in new ways, leveraging talent and influencers via social channels, streaming services and digital media.”

“We’ve partnered with W2O since starpower’s inception and have always shared similar philosophies about maintaining an entrepreneurial spirit, the power of data, and a passion for powerful human storytelling,” said Lalin. “Given the extraordinary growth in branded entertainment and influencer marketing, it’s a natural time for us to join forces. This partnership will bring W2O’s fully integrated marketing and communications offerings to our existing clients in health and wellness, consumer and beauty, and to new clients, giving us the ability to deliver across the entire spectrum of client needs.”

W2O and starpower have worked together on numerous campaigns over many years. This new partnership, which will further leverage starpower’s expertise and access, will bring a seamless, integrated approach to W2O’s clients.

The starpower team will operate under W2O’s single, integrated profit and loss (P&L) operation. The team will have access to W2O’s proprietary data models and tools as well as its 1,500-person strong multidisciplinary team – including data analysts, scientific strategists, branding experts, communications specialists and creatives – to build unfair advantage for clients and their brands. The starpower leadership team will remain the same.

W2O’s approach to growth is to add experts and capabilities that address client needs and recommendations. This is the eighth acquisition W2O has completed since the company announced its partnership with New Mountain Capital about a year ago. This partnership and series of acquisitions continue to strengthen W2O’s offerings and further position the company as a go-to partner of choice to help clients accelerate clinical trials, achieve commercial success, and navigate and engage their stakeholders in an increasingly virtual, social and digital post-COVID-19 pandemic reality.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Tags:

New Tech-Driven Patient Activation Organization Combines Data, Behavioral Economics and Decision Science to Increase Speed and Reduce Costs

Launch of Hū Designed to Address Broad Clinical Trial Enrollment Challenges Heightened by COVID-19 Pandemic 

San Francisco, September 29, 2020 W2O today announced the creation of , the first-of-its kind Patient Activation Organization (PAO). Hū will usher in a new era of patient activism and engagement, resulting in access to better health and well-being. Hū’s unique approach combines data, behavioral economics and decision science to unlock drivers of human behavior – how people make decisions, what they value, what motivates them, what they fear and more – in order to give people a central role in every facet of the clinical trial experience.

An unprecedented decline in people’s willingness to participate in clinical trials threatens the development of new therapeutic, vaccine and device breakthroughs. In the past year, willingness to participate in clinical trials has plummeted from 85% to just 49%, according to Centerwatch. While technology and big data have changed the ease with which potential clinical trial participants are identified, until now, no one has used social and behavioral evidence to quantify the motivations that drive increased participation. Hū – short for hūman but long on humanity – is taking an approach that promises to bring a dramatic shift in participation rates, and the optimization of speed, cost and quality in research and development.

“We’re not bound by the way things have been done before, so we’re free to reimagine the potential of clinical trials and bring them to life in ways that will reshape how we think about, organize and conduct them,” said April Lewis, EVP and General Manager at Hū. “We’re at an inflection point where the consumerization of healthcare and the changes in attitude accelerated by COVID-19 demand that we take meaningful action to amplify the patient voice as a driver of R&D success. And we at Hū are uniquely positioned to affect change at scale.”

Hū is led by Jayson Dupré, D.O., M.B.A. Dr. Dupré joined W2O through the acquisition of 21GRAMS where he continues to serve as President. Recognizing the opportunity to leverage W2O’s proprietary analytics, insights, and creative to address challenges in clinical trial patient activation, Dr. Dupré tapped industry veteran, April Lewis, to be General Manager at Hū. With 20 years of success innovating and disrupting clinical trial operations across pharma and clinical research organizations, Lewis was part of the Quintiles/IMS executive merger team and Head of Trial Operations and Site Engagement Products at GSK.

The Hū vision has inspired leading experts from across the pharmaceutical sector to join the leadership team, including:

  • Jason Tse, EVP, Strategic Development, was previously with Pharma Intelligence where he was Head of Strategic Partnerships and M&A
  • Alexandra Charge, SVP, Offerings and Marketing, who was previously Global Head of Process and Enabling Solutions with AstraZeneca R&D
  • Ying Jiang, SVP, Delivery and Customer Success, who joined from IQVIA where she was Global Offerings Lead, Clinical Cost Benchmarking
  • Ronnie Du, SVP, Clinical Data and Offerings, who was previously Principal Data Scientist, Center for Design and Analytics at Amgen
  • Eric Roberts, VP, Trial Diversity & Inclusion, who was previously at Arnold Worldwide and a is career champion for multi-cultural communications
  • Alex McSherry, VP, Sales, was previously at IQVIA and Oracle where he led global business development efforts with major pharmaceutical clients

For more information on Hū, please visit www.WelcomeToHu.com and connect with us on LinkedIn.

A Revolution in Clinical Trials, an Evolution for W2O

Inspired by W2O’s analytics-driven, digital-first approach, Hū is the next step in W2O’s journey to use data and creativity to improve how healthcare is delivered, experienced and integrated into our daily lives. Clinical trials are a natural extension of W2O’s deep heritage of working from bench to bedside. W2O has been strategically broadening capabilities to become the clinical, commercial and corporate partner of choice to healthcare companies. The company’s growth is driven by the goal of advancing client needs in an increasingly virtual, social and digital reality, accelerated by the current pandemic.

“Forming Hū was a strategic choice, intended to speed up real, meaningful change in the clinical trial arena and is part of our own transformation into a global health innovation company,” said Jim Weiss, Founder and CEO of W2O. “Our vision has always been to make the world a healthier place by helping our clients make healthcare more accessible, equitable and beneficial to patients, providers and ultimately society. Hū gets us closer to that ideal.”

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com and connect with us on Twitter, LinkedIn and Facebook

# # #

Contact:

W2O

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Tags:

San Francisco and New York, September 24, 2020 W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, today announced it has acquired Elysia Group, a health economic and outcomes research (HEOR) consulting firm operating in the United States and Asia Pacific. Founded in 2014, Elysia provides pharmaceutical and medical device clients with innovative modeling approaches to health economic strategy and evidence development using data and analytics and real-world evidence.

Elysia Group will collaborate and integrate closely with Discern Health, which W2O recently acquired. Discern Health counsels leading healthcare organizations on the performance measures and innovative payment models that shape the market for their products and services.

“We are building our organization to help our clients stay ahead of the evolving healthcare policy, consumer and payor landscape,” said Rita Glaze, Practice Leader, Commercial Strategy and Market Access, at W2O. “The collective expertise and capabilities of Elysia and Discern enable us to help clients plan for and execute their commercial and market access strategies at greater quality and depth than ever before.”

Elysia Group Co-Founder and CEO Bruce Wang and Co-Founder and President Wesley Furnback have joined W2O as Health Economics and Real-World Evidence Practice Leaders reporting to Glaze. Together, these leaders will expand the firm’s offerings in economic modeling and real-world evidence with greater international reach and perspective.

“Joining W2O is a win-win,” said Wang. “Our value-focused capabilities combined with W2O’s data and technology platforms will be a true industry differentiator, adding more insights and value to our modeling and real-world data products. We look forward to leveraging our established relationships in the Asia Pacific market alongside W2O’s unique set of offerings and expanding the firm’s footprint in this important area.”

Prior to founding Elysia Group, Wang led the Health Economics & Outcomes Research group for Alliance Life Sciences as Vice President. He earned a Ph.D. in economics from the University of Washington and a B.A. in economics from Columbia University. Furnback served as a Senior Consultant at Alliance Life Sciences prior to founding Elysia Group. He received a Certificate in Health Economics & Outcomes Research from the University of Washington and earned a B.A. in economics from the University of Maryland, College Park.

“Our existing clients in the HEOR and market access space will benefit from the added services and solutions that W2O has to offer – all of which are based on data – from bench to bedside,” added Furnback. “Value-based care has never been more important, and we look forward to bringing our unique expertise to W2O’s unmatched roster of life sciences companies.”

W2O’s approach to growth is to add experts and capabilities that address client needs and recommendations. This is the seventh acquisition W2O has completed since the company announced its partnership with New Mountain Capital in 2019. This partnership and series of acquisitions continue to strengthen W2O’s offerings and further position the company as a go-to partner of choice to help clients accelerate clinical trials, achieve commercial success, and navigate and engage their stakeholders in an increasingly virtual, social and digital post-COVID-19 pandemic reality.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Tags:

Despite Pandemic Headwinds, Firm Heading Toward 50% Growth in 2020

San Francisco, September 16, 2020W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, announced today it has hired top talent from some of the world’s largest and most successful companies to continue its transformation into a global health innovation company.

“As healthcare becomes more personal, consumerized and digitized, W2O is firing on all cylinders – innovating and growing approximately 50 percent – in the face of unprecedented circumstances for our industry and the world,” said Jim Weiss, Founder and CEO of W2O. “The people who have joined us bring expertise, agility, leadership and relationships that will help our clients go further, faster, and ultimately achieve our vision of making the world a healthier place.”

W2O’s entrepreneurial spirit, 20-year track record of success, and vision for the future have attracted leaders from many of the world’s leading brands and organizations. These new hires are igniting solutions and providing strategic counsel to meet client business needs – now and in the future – helping W2O become the clinical, commercial and corporate partner of choice.

  • Julie Adrian – Global Chief Experience Officer
    • Adrian is integrating the best data-driven, creative and results-oriented approaches and bringing W2O’s customized capabilities and technologies together.
    • She is a 25-year veteran of the healthcare industry and inductee into the PharmaVoice100, with a background that includes agency leadership and in-house experience.
  • John Capodanno – President, Financial, Corporate & Capital Market Communications
    • Capodanno is growing W2O’s corporate communications and capital market offering to meet the evolving needs of life science companies.
    • He led the Healthcare & Life Sciences practice at FTI Consulting and drove one of the largest transactions in healthcare and a re-positioning of one of the industry’s largest R&D functions.
  • Nikki Levy – Practice Leader, Advocacy Relations
    • Levy is building a new practice to help clients create mutually beneficial relationships and ultimately achieve better patient outcomes.
    • She has more than 25 years of experience at companies through all stages of development including Genentech, Vertex, Alkermes and Wave Life Sciences, and was named to the PharmaVoice100 list.
  • David Magrini – President, CRM and Marketing Solutions
    • Magrini is building on W2O’s data and marketing technology foundations to develop performance marketing strategies and scalable CRM offerings to bring integration and measurable solutions to clients
    • He led the health practice for 10 years at Merkle, expanding its client base and growing it to become a Top 15 Healthcare Agency in the U.S.
  • Jane Petrino – Practice Leader, Communications Strategy
    • Petrino is leading a fast-growing team of integrated communication strategists.
    • She was the Managing Director of RXMOSAIC, where she led through double-digit growth for each of her years at the helm.

In a business based on people, W2O has also strengthened its human resources and talent acquisition teams with multiple leaders. Together, these leaders will retain, attract and build a diverse, equitable and inclusive workforce of the future for a new kind of health innovation company.

“Hiring, retaining and growing the best people is the foundation of our success. That’s the one constant in our ever-evolving business,” said Jennifer Gottlieb, Global President of W2O. “To do this, we are thinking completely differently about our people. We listen. And we use our own data to understand what motivates them, how to reward them, how to inspire them, and how to give them opportunities that go beyond what others offer. That’s what this dream team is doing.”

  • Marlena Edwards – Head of People and Performance
    • Edwards is ensuring our people can be their best and do their best work for clients.
    • She is a 15-year agency HR veteran, and was previously Chief Talent Officer at Huge, where she designed and drove talent strategies that fostered cultural connection, diversity and inclusion, productivity and retention.
  • Carrie Galli – Head of Organizational Growth and Planning
    • Galli is future-proofing how our people will succeed by improving how we work.
    • She joins from Golin Harris, where she served as Executive Vice President, Human Resources, implementing effective and innovative talent management practices.
  • Jonathan Robbins – Head of Talent Acquisition
    • Robbins is bringing the best people to W2O using tech-enabled and data-driven approaches.
    • He has successfully built, driven, led and delivered talent acquisition, engagement and development for organizations including Interbrand, frog design, IDEO, R/GA Nike and Microsoft.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved nearly 20 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,500 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com

Follow W2O on Twitter

Follow W2O on LinkedIn

Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Tags:

W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced findings from a research study on consumer attitudes toward data privacy, specifically personal health data.

The study, Consumer Attitudes on Health Care Data Uses and Privacy, was conducted in two waves – before and during the COVID-19 pandemic – to understand the overall perceptions of data privacy, gain insights into consumer awareness about data usage, and better understand consumers’ willingness to share health data. The study can be found here.

The findings indicate that before people will be confident in sharing their health data, they need education and information about how their data will be used. Consumers want control over their health data, including a permission-based system to share data, and the ability to opt out at any time. According to the survey, 70% of participants said they believed that health data should either not be shared or shared only with their permission.

Consumers also care most about the altruistic purposes of health data use. Nearly half of those surveyed indicated that they would only want their health data shared if they knew it would be used to improve healthcare outcomes for others. As a result, organizations should clearly outline how they are sharing and using health data, and how it can advance public health.

“Data is essential to driving progress and innovation in healthcare. The COVID-19 pandemic and interventions such as contact tracing and related technology applications have created an urgent need for companies to provide greater clarity around how health data is used,” said Dan Linton, Global Data Privacy Officer for W2O. “Consumers believe that their health data is private information and should be used to advance their health and public health in general. To achieve the advances possible to address COVID-19 and beyond, organizations must proactively consider and respond to these privacy concerns.”

The study was conducted as a 20-minute quantitative survey in September 2019 and a 25-minute online quantitative survey in May 2020 with more than 1,000 consumers who broadly represent the overall U.S. population. The findings indicate that consumers’ levels of concern over data privacy have increased since the pandemic began. Respondents in Wave 2 expressed more concern about their ability to keep their health data private compared to Wave 1, with 50% in the second wave extremely concerned versus 46% in the first wave.

Highlights of the survey findings include the following:

  • Data privacy, and particularly health data privacy, is crucial to consumer trust – 68% of respondents say that they factor in a company’s reputation for privacy protection when making decisions to engage with the organization.
  • Education about the critical need that health data can fulfill is a problem – The study showed that consumers are unclear about who may be collecting their health data or how it is being used. Unaided, 34% of respondents were aware of insurance companies collecting their health data, but only 5% identified health websites and applications.
  • Consumers want privacy protection and informed choice – 70% of respondents believe that health data should either not be shared or shared only with their permission.
  • Consumers are more likely to share health data for altruistic reasons– 44% indicated that they would only want their health data shared if they knew it would be used to improve healthcare outcomes for others. Only 24% of respondents believe data is collected to develop new therapies and only 29% believe it is being used to improve healthcare outcomes.
  • Fewer than 30% of Baby Boomers (ages 55 to 75), a group that might benefit most from COVID-19 interventions, indicated a willingness to download a COVID-19 contact tracing application compared with about 65% of Millennials (ages 25 to 39) and Generation Z (ages 18 to 24). Control, anonymity and the ability to delete data increased the likelihood that consumers surveyed would download the contact tracing app.

“This study is indicative of the need to continually gather the most valuable, data-driven insights to better inform strategies and solutions for improved health outcomes,” said Kevin Johnson, Group President and Managing Partner at W2O. “Understanding consumer attitudes and expectations is essential for organizations and leaders to adequately address such turbulent, transformative periods in the healthcare industry. As the implications of COVID-19 continue to unfold, these insights are more valuable than ever.”

Full results of the research study and an infographic can be found here.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved 18 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,400 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Contacts

Sylvia Aranda, 424.201.9464
saranda@w2ogroup.com

Tags:

Sixth acquisition in just over a year deepens firm’s value, access and pricing insights, policy, communications, marketing and consulting capabilities

San Francisco and Baltimore, July 28, 2020 – W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector, today announced the acquisition of Discern Health. This health economics and outcomes research (HEOR) consulting firm provides strategic direction and policy solutions to life sciences companies, government and nonprofit agencies, and health insurers.

Discern Health counsels leading healthcare organizations on the performance measures and innovative payment models that shape the market for their products and services. Discern Health also works closely with organizations to strengthen and quantify clinical and real-world evidence strategies that inform ongoing market access and commercialization initiatives. Discern Health’s staff previously held roles within leading organizations including the Centers for Medicare & Medicaid Services (CMS), the National Quality Forum (NQF), and the National Committee for Quality Assurance (NCQA). Discern has offices in Baltimore and Washington, D.C., further expanding W2O’s presence with now nearly 100 people dedicated to these increasingly important health policy arenas.

“Value-based care is a key driver of health system change,” said Guy D’Andrea, Founder and Managing Partner of Discern Health. “To be successful, health care companies need to integrate value-based strategy into each level of their organization and each stage of product development.”

“We’ve been working with W2O over the past year and have gotten to know each other well,” added Tom Valuck, M.D., J.D., Partner at Discern Health. “Being part of the W2O team means that we can supercharge our capabilities and incorporate world-class analytics and insights into our work, bringing even greater resources to our clients and, ultimately, improving patient outcomes.”

This is the sixth acquisition W2O has completed since the company announced its partnership with New Mountain Capital just over a year ago. W2O’s approach to growth is to add experts and capabilities that its clients recommend. This approach continues to strengthen W2O’s offerings and positions the company as a go-to partner of choice to help clients accelerate clinical trials, achieve commercial success, and navigate and engage all their stakeholders in an increasingly virtual, social and digital post-COVID-19 pandemic reality.

“Value-based metrics, the continued need for real-world data integration, and the changing landscape of federal, state and international health policy in the face of the COVID-19 crisis are impacting healthcare faster than ever before,” said Rita Glaze, Practice Leader, Commercial Strategy and Market Access at W2O. “Our clients need ongoing evidence-generation strategies that mirror the market dynamics they are facing, along with up-to-the-minute insights and counsel. This information is vital to guide policy positions and commercial decisions that will unlock maximum value for their products, solutions and services. With Discern Health as part of our organization, we will continue to raise the quality and depth of our data and analytics offering, to ensure it stands up to the scrutiny of peer and government review. We will truly be #BetterTogether.”

The Discern team will operate under W2O’s single, integrated profit and loss (P&L) operation, with access to all of W2O’s proprietary data models and tools as well as its 1,400 person strong multidisciplinary team – including data analysts, scientific strategists, branding experts, communications specialists and creatives – to build unfair advantage for clients and their brands. Additionally, the Discern leadership team will remain the same.

About W2O

Founded by Jim Weiss in 2001 and built on an ethos of entrepreneurship, staying fluid and doing the right thing, W2O has achieved 18 years of uninterrupted growth while remaining fiercely independent. W2O is an alchemic mix of 1,400 people and hundreds of clients and partners – working from bench to bedside – to make the world a healthier place.

Driven by data, W2O applies proprietary analytics and best-in-class technology to build insights that power creative ideas and concepts. W2O seeks to become the partner of choice to empower optimal healthcare knowledge, access and outcomes – now and in the future.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Patrick Lynch, 516-574-3501

plynch@w2ogroup.com

Tags:

Former Havas Lynx Executive and President of the Health and Wellness Jury at Cannes will help firm create a global healthcare creative force

 New York, July 13, 2020 21GRAMS, a breakout healthcare firm and one of W2O’s operating firms, is doubling down on creativity with the appointment of Tom Richards as Co-Global Chief Creative Officer. In this role, Richards, who is based in the U.K., will serve as a creative partner to U.S.-based Frank Mazzola, one of the company’s founding members. Together, the vision is clear: Raise the value of healthcare brands and companies to be more relevant, meaningful and human.

Richards joins 21GRAMS from UK-based Havas Lynx, where he served as Chief Creative Officer. During his tenure, he grew the creative department to more than 100, led the company to win the Lions Health “Healthcare Agency of the Year” in 2018, and helped it become one of the UK’s top 10 creative agencies in 2019. Richards is also President of the Health and Wellness jury at Cannes, which he will lead in 2021.

“With an internationally recognized talent like Tom partnering with Frank, our reach and scope now extends globally,” said Robert Blink, Founder and CEO of 21GRAMS. “This shared role gives our clients two game-changing creative leaders who, together and across every account, regardless of geography, will oversee, elevate and push the creative work to places healthcare hasn’t been. Working collaboratively, they will strive toward their vision of raising the value of healthcare brands and companies to be more relevant, meaningful and human.”

21GRAMS’ advertising and marketing expertise in the healthcare sector coupled with W2O’s best-in-class data, analytics and insights provides organizations and brands with the knowledge and precision to build and nurture relationships among key stakeholders to drive business results. Acquired by W2O in January 2020, 21GRAMS broadens W2O’s advertising portfolio while elevating its overall offering with the most advanced data and analytics in the industry. The goal is to be “the first at what’s next in healthcare” by breaking down walls among PR, advertising, analytics and medical communications for a fully connected solution set that supports the rapidly changing needs of the healthcare industry.

“Ask any agency in health, around the world, who would be on their wish list,” said Co-Global Chief Creative Officer, Frank Mazzola. “9 out of 10 will say Tom Richards. The work he’s led consistently shows the industry what great looks like. Not just in ideas that break the norms of traditional advertising, but in craft. As someone who came up in copy, and Tom in art, we complement each other well. I’ve been a fan for years, so it’s an honor to partner alongside and see what we can do together. The goal is to open doors no one knew existed for the industry.”

“I have always admired 21GRAMS and its philosophy of finding what makes people tick, and creating work that really ‘gets’ them. Work that doesn’t just compete with other brands, but anything fighting for the audience’s attention,” said Richards. “It’s not every day you get to be a part of, and help build, a new kind of health agency – one with a passion for creativity at its heart and soul. The leadership team has great chemistry and delights in doing things differently, and I’m thrilled to be a part of it.”

About 21GRAMS

21GRAMS was built to be different by design, fusing advertising and education for the first time in an agency model. As two arms of the same body, these disciplines work seamlessly, to inject creativity into education and give advertising exclusive and personal access to doctors and patients – providing an unmatched ability to uncover deeper insights and create work that truly “gets” them. Using brands people love as a model for connecting with audiences, 21GRAMS adheres to the mantra “Medicine should be more inspiring than sneakers.” Obsessing less on minutia, and more on what makes people tick. For more information, visit 21GRAMSNY.com.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

 

Tags:

San Francisco, June 22, 2020 – Jennifer Gottlieb, Global President of W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, has been named to the Board of Directors for the Muscular Dystrophy Association (MDA).

“I am honored to join MDA in its mission to improve the lives of people and families affected by neuromuscular diseases, especially given how vulnerable the population is during the current COVID-19 crisis,” said Gottlieb. “I look forward to bringing my deep healthcare experience to MDA to expand fundraising efforts and digital-enablement in support of innovations in science and care.”

MDA is committed to transforming the lives of people affected by muscular dystrophy, ALS and related neuromuscular diseases. Through innovations in science and care, MDA is creating more hope and answers for families living with muscular dystrophy and related diseases that take away physical strength and mobility. Research supported by MDA is directly linked to approved, life-changing therapies across multiple neuromuscular diseases. Additionally, MDA supports the largest network of multidisciplinary clinics providing best-in-class care at more than 150 of the nation’s top medical institutions. Each year, thousands of children and young adults with neuromuscular diseases learn vital life skills and gain independence at MDA’s summer camp and through recreational programs, at no cost to families.

“At this challenging time, we must remember that many diseases, especially neuromuscular diseases such as muscular dystrophy, spinal muscular atrophy, and ALS, urgently need innovations in research and care. MDA is an essential charity, and our patients are more vulnerable than ever. We are on the front-line delivering care to over 50,000 people and bringing critical education and resources to over 250,000,” said MDA President and CEO Lynn O’Connor Vos. “Jennifer’s passion, commitment and deep industry knowledge will help ensure that we increase our impact and continue to transform the lives of people affected by neuromuscular diseases, during this critical time and beyond.”

For more information about MDA, please visit its website at www.mda.org, or click here to access W2O’s “What2Know” podcast interview with O’Connor Vos.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773-343-3069

pduckler@w2ogroup.com

Tags:

Firm Also Receives Recognition in Multiple Categories

San Francisco, June 10, 2020 – W2O received multiple awards at the 2020 North American SABRE Awards, including “Large Agency of the Year” and “North American Agency of the Year.”  Considered the premier awards program for the PR industry, SABRE awards are given by PRovoke Media following an exhaustive research process involving more than 150 submissions and 50 face-to-face meetings with the best PR firms across the United States and Canada.

“Winning this year’s North American SABRE Awards is an immense source of pride and affirmation of the work we’re doing on behalf of clients to make the world a healthier place,” said Jim Weiss, Founder and CEO of W2O. “Our amazing group of professionals inspire me and each other with their relentless dedication to be the best. That attitude and behavior permeate our culture and partnership with clients, representing the foundation of our firm.”

In addition to winning the “Large Agency of the Year” and “North American Agency of the Year” categories, W2O was also recognized for the following achievements:

  • Placed second in the “Agency of the Decade” category.
  • Placed second in the “Best Large Agency to Work for” category.
  • Shared a first-place win with client Stallergenes Greer in the “Animal Health” category for “Augmenting Reality to Build an Engaging NAVDF Booth Experience for Vets.”

“Our 18 consecutive years of double-digit growth and success makes us the first agency to break into the large agency category in more than a decade,” said Jennifer Gottlieb, Global President of W2O. “These awards are further proof that our strategy of bringing the best people, purpose and creativity together with great healthcare clients continues to achieve extraordinary results.”

In addition to the SABRE awards, W2O was recently awarded more than 100 awards from several premier organizations, including:

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 773.343.3069

pduckler@w2ogroup.com

Tags:

Acquisitions, Organic Growth, Hiring Enables Firm to Partner with Clients Looking to Thrive in a Future-First Era with Deeper, More Expansive Technology and Scientific, Creative Offerings

Firm Adapts to New Normal by Offering Staff Flexibility, Mental Health and Childcare Support while Sheltering in Place

San Francisco, May 20, 2020 – W2O reported 2019 revenue increased by 26% to $223 million from $177 million in 2018 and improved operating profit. The company, which was recently recognized as a North American Agency of the Decade by PRovoke Media, has reported double-digit revenue growth since its inception in 2001. Growth was due to a combination of organic client expansion, new client partnerships, and the addition of new capabilities and offerings through hiring and acquisitions.

“Our growth this past year is even more remarkable because we achieved it while completing the sale of our firm, which resulted in an exciting partnership with New Mountain Capital,” said Founder and CEO Jim Weiss.  “Since then, we have completed five game-changing acquisitions and generated new and organic business growth, putting us on track to achieve over $300 million in revenue in 2020. We quickly adapted to a new normal and invested in our people so they can continue to deliver for their clients and their families while sheltering in place during this pandemic crisis. We are teaming up with clients and organizations focused on testing, tracking and new treatments to fight COVID-19 with everything they and we have got!”

Among the many initiatives W2O is supporting pro-bono are a COVID-19 news tracker with the California Life Sciences Association (CLSA) and the VentilatorSOS program with UC Berkeley.

Acquisitions

Five newly acquired firms have bolstered W2O’s science communications, medical education, creative, technology and digital capabilities and added more than 60 Ph.D. and M.D. staff members across the United States and Europe:

  • Arcus Medica: A deep bench of doctoral-level experts who specialize in translating complex clinical and scientific data into clear, meaningful content to help brands influence key audiences in today’s evolving healthcare environment
  • ISO.health: UK-based scientific and medical industry experts who create scientific educational programs for pharmaceutical, biotech and life sciences companies and organizations
  • Radius Digital Science: A scientific, digital, creative agency translating complex science into immersive, easy-to-understand creative experiences for healthcare brands
  • 21GRAMS: A rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human
  • Symplur: A social media analytics platform exclusively focused on the healthcare sector

W2O continues to build and expand its technology-based tools and platforms to provide real-time information, consumer sentiment and insights that inform highly tailored and results-oriented marketing communications approaches for its clients. In early 2020, W2O entered into a licensing agreement for access to HIPAA-compliant medical and pharmacy claims and electronic health record data. Coupled with the firm’s other non-traditional real-world data (RWD), W2O has new and unique views into the clinical landscape to help clients improve clinical decision-making, patient access and health outcomes.

Our People and Clients

Experts from across the technology, healthcare and marketing communications industries joined the firm in 2019, with more than 25 hires in leadership roles. Bringing leaders from diverse backgrounds complements the firm’s rich healthcare focus and drives new thinking for clients, bringing the best from multiple industries to the healthcare sector in an integrated fashion.  These leaders join W2O at a time when the focus on culture and employee engagement has never been stronger, as W2O has expanded wellness, mental health, childcare support and flexibility offerings for employees in response to the COVID-19 pandemic. The firm’s culture and experience has resulted in being recognized as a Best Agency to Work for by AdAge, MM&M, PRovoke, PRWeek and PRNews. W2O has also been shortlisted for Large Agency of the Year by MM&M, Medical Advertising News, PRWeek and PRovoke.

W2O partners with clients to create innovative work, using an integrated and data-driven approach to set clients apart from their competition and reach stakeholders in new, more personal ways. This work resulted in W2O winning more than 100 awards in 2019.

“The future is now with organizations being expected to lead and shape with purpose and meaning and maintaining relevance for greater innovation, connectivity and empowerment, added Weiss. “Driving this new ecosystem is a discover-based marketing and communications model allowing stakeholders to engage in real-time, accelerating learning, confidence and trust.”

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs more than 1,300 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Tags:

Accelerates Firm’s Evolution to Drive Consumerization and Digitization of Healthcare

San Francisco, May 4, 2020 – W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, announced today that Bryan Specht has been named Group President, Transformation, Consumer Activation and Marketing. In this role, he will expand W2O’s healthcare offering to include additional consumer-focused, tech-enabled and digital capabilities, accelerating its transformation to a digital healthcare firm.

With five acquisitions in the past seven months, W2O has been readying for further disruption and consumerization of healthcare, which has been accelerated by the COVID-19 pandemic. Specht will lead integration of people and technology across the firm, creating new ways to work with clients and potential partners to redefine how people experience healthcare and manage their personal health. A recognized transformation leader, Specht brings deep understanding of change management to accelerate W2O’s evolution.

“Current events are escalating the disruption and transformation happening in the healthcare industry, which is leveraging telemedicine, genomics and other data-based, digital experiences to improve people’s health and wellness,” said Jim Weiss, Founder and CEO of W2O. “Bryan understands the human side of healthcare and that patients expect real-time, personal and direct access to health information. As a firm, we have been on a journey to infuse the marketing principles of the consumer and influence world with science and healthcare to reach people in new ways, giving them more control to live healthier lives. Bryan will accelerate and dimensionalize these assets, resulting in a truly digital healthcare firm.”

Specht previously served as Chief Growth and Innovation Officer and was a key architect in launching ICF Next, a global consulting agency built through the convergence of 10 different award-winning marketing, engagement and digital businesses. Before ICF, Specht was president of Olson, overseeing the firm as it received a long list of industry honors including multiple agency of the year distinctions and more than a dozen Cannes Lions. A respected thought leader and change agent in the industry, he was three times named to PRWeek’s Power 50 List and was named to PRovoke’s Innovator 25.

“I am energized by the purpose, entrepreneurialism and incredible 18-year track record of double-digit growth at W2O,” said Specht. “Now is the time to harness W2O’s technology, data, creativity and marketing communications expertise to deliver some of the most important and meaningful engagement in the lives of people each and every day. As we’re witnessing with the current pandemic, W2O’s mission to make the world a healthier place through marketing communications has never been more important.”

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. The firm employs nearly 1,400 people in 18 offices across the United States and in Europe, and partners with a growing roster of Fortune 500 organizations, including 23 of the top 25 pharmaceutical companies.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Tags:

Immediately Enhances Ability to Precisely Listen, Target and Engage with Key Influencers, Customers and Stakeholders —

— Firms Currently Collaborating to Track Critical COVID-19 Conversations —

San Francisco, Calif., April 14, 2020W2O, the leading independent provider of analytics-driven, digital-first marketing communications to the healthcare sector, today announced the acquisition of Symplur, a social media analytics platform exclusively focused on the healthcare sector.

Symplur provides an easy-to-use interface and analytical capabilities that will help make W2O’s data and analytics operating system and technology accessible to a broader range of non-technical users. In the future, W2O will add new features and products to the platform that will further be informed by and benefit its wide range of healthcare clients.

Symplur’s proprietary, purpose-built social media analytics platform – the only tool of its kind on the market designed entirely for healthcare – allows for the rapid and easy identification of social media trends among physicians, patient advocates, life science professionals, media and other key audiences of interest to healthcare organizations, government entities and academic institutions. Through a collaboration with the California Life Sciences Association, W2O and Symplur are already utilizing the platform in conjunction with W2O’s proprietary data and technology stack to track COVID-19-specific conversations and trends across the healthcare ecosystem.

“Particularly in these challenging, uncertain times reverberating across global communities and economies, healthcare companies are looking to track essential information in an urgent and immediate manner utilizing data and analytics to discern insights for decision-making,” said W2O Founder and CEO Jim Weiss. “Symplur’s pioneering technology products turn up the volume on the most important, and often overlooked, voices in healthcare, ultimately engineering a path to a deeper understanding of this dynamic, complex sector. Symplur is another in a series of strategic investments in people, technology and platforms that we’ve made, and intend to make, to strengthen the solutions we provide to clients. W2O now has hundreds of people focused in technology, data science, audience analytics, activation and measurement and we will double down in this space going forward.”

The acquisition is designed to expand W2O’s proprietary data and technology platform and corresponding solutions, further enabling the firm to focus on combining data-rich intelligence with technology to solve clients’ problems in real-time, successfully communicate and market their product offerings, and drive overall value for their brands.

“Insights derived from social media analytics are significantly impacting the entire healthcare ecosystem. Our massive Healthcare Social Graph® platform, which uses machine learning, enables us to extract the most valuable insights to meet the needs of a diverse range of healthcare clients and ultimately drive their priorities forward,” said Audun Utengen, Symplur co-founder and CEO. “This work over many years has helped us expedite the development of relevant, powerful technology platforms like those used to help track critical COVID-19 conversations from authentic, expert sources.”

Symplur’s technology and intelligence reports are currently utilized by pharmaceutical companies and government agencies, including the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Diseases (NIAID).

Symplur and W2O are privately held companies, and the financial terms of the acquisitions are not being disclosed. This acquisition, which was completed in partnership with W2O’s private equity partner, New Mountain Capital, marks the firm’s fifth acquisition in nine months. Symplur, which will now operate as W2O symplur, adds a team of seasoned software architects and developers to the W2O family. Symplur co-founders Utengen and Thomas Lee will continue to serve in leadership roles and be key participants in the development of the firm’s audience planning product suite.

“Audun, Thomas and their highly adept team will strengthen our audience planning, intelligence and engagement capabilities while helping enrich our data taxonomy and making our technology platform and offerings more robust, automated, faster and easier to use,” added Adam Cossman, W2O’s Group President and Managing Partner, Technology Products & Solutions. “We look forward to developing additional end-to-end integrated marketing communications tools fueled by technology, taking what we already do for clients and increasingly automating it – turning our services into technology-driven solutions for which our clients are clamoring. To that end, we continue to look for innovative companies and technology that can enrich our offering in these critical areas.”

About Symplur

Headquartered in Pasadena, Calif., Symplur’s unmatched social media analytics platform tracks how physicians and other healthcare stakeholders produce and consume medical information online, which increasingly appears in free, open-access environments such as Twitter. Its proprietary Healthcare Social Graph®, the world’s largest database of its kind, comprises over tens of thousands of healthcare topics with billions of conversations around any given therapeutic area among millions of influencers in real-time. This unique platform empowers users to learn from the expertise shared publicly by patients, clinicians and other relevant stakeholders. Symplur’s additional solutions-oriented capabilities include influencer analyses, which utilize proprietary recursive algorithms to accurately identify the true influencers in any given healthcare topic; stakeholder segmentation, which identifies and categorizes the people behind the conversations; classification, which combines human curation and automated processes to organize, structure and appropriately categorize raw social data; and engagement analyses, which measure levels of engagement to determine what is resonating and driving conversations.

About W2O 

Founded by Jim Weiss in 2001, W2O seeks to make the world a healthier place through marketing communications. The Company applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business and organizational results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

# # #

Contact:

Peter Duckler, 310-774-3425

pduckler@w2ogroup.com

Tags:

Fast-growing Breakout Agency Brings Bold Creative and Deep Insights-Driven Approach to Global Healthcare Clients

SAN FRANCISCO & NEW YORK–(BUSINESS WIRE)–W2O, the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector, today announced the acquisition of 21GRAMS, a rapidly growing, strategic and creative marketing, advertising and patient/medical education agency dedicated to making healthcare more human.

The transformative acquisition will further strengthen W2O’s creative firepower and expand its capabilities in direct-to-consumer (DTC), direct-to-provider (DTP) and business-to-business (B2B) advertising and marketing to support the rapidly changing needs of the healthcare industry. 21GRAMS brings a differentiated method of fundamentally understanding a healthcare brand’s audience to ultimately make advertising less of an interruption and more worth their time, attention and action, while also offering a comprehensive suite of bold creative content capabilities. Together, W2O and 21GRAMS are committed to breaking down walls between the disciplines of advertising, marketing, communications and medical education to ensure a fully connected, inspiring and meaningful experience for patients, physicians and the entire healthcare ecosystem.

“21GRAMS is a true innovator, offering something different and more profound than its competitors. The agency’s philosophy that the work can and should tap into the human spirit, inspiring the invisible ‘something’ inside, aligns directly with our patient-first ethos and to what we are doing for clients. The unique strengths of 21GRAMS immediately enhances what we’ve been building over the last few years at W2O, a truly integrated approach to marketing communications. From my days as a client, I’ve always believed in the strength of a multi-disciplinary team spanning advertising, digital, branding, media activation and engagement working together in unison to deliver optimal business results,” said W2O Founder and CEO Jim Weiss. “Together, we will combine our experienced, results-oriented teams, integrating the best in proprietary data and analytics, creative content, and omnichannel activation to create a next-generation entity that’s equal parts technology and science – providing clients with a level of expertise that compares more to Netflix or Google than any network that currently exists. Simply put, we are joining together to be the first at ‘what’s next’ in health.”

This acquisition also bolsters W2O’s position in medical and scientific communications, as 21GRAMS has a robust medical and patient education division that will complement the three recent W2O acquisitions of Arcus MedicaISO.health and Radius Digital Science. This will allow for deeper engagement with healthcare influencers, which is critical to W2O’s bench to bedside approach. W2O works with more than 100 healthcare companies, from innovative start-ups to 24 of the 25 largest global pharmaceutical companies as well as some of the leading payors and providers.

“W2O has been leading the charge in health’s tech revolution, combining intelligence with the latest technology to provide an unfair advantage for brands and organizations – not at the speed our industry is accustomed to, but in real-time to elevate the overall value and relevance of healthcare marketing and communications in today’s chaotic, digital-first world,” said Robert Blink, Founder and CEO of 21GRAMS. “Joining this like-minded and forward-thinking organization gives us greater scale, as well as significant technological innovation and global reach – allowing us to match our ambitions to our abilities. Together, we are designing the future in health, connecting humanity and technology to position healthcare brands as more inspiring than sneakers, fast food or soda water.”

Over the last several years, W2O has significantly expanded and strengthened its overall portfolio, including its advertising and digital capabilities. Having curated a team of more than 200 of the industry’s leading professionals, W2O has been producing and executing innovative, award-winning marketing programs fueled by the organization’s proprietary data analytics platform. This approach measures success based on the impact it’s had on a client’s business performance. 21GRAMS adds more than 150 advertising and patient/medical education specialists to the W2O family. With extensive experience in working with healthcare brands across all major therapeutic areas and developmental stages, 21GRAMS’ core capabilities include advertising (direct-to-consumer and healthcare provider), patient storytelling, medical education, strategy, analytics and television production.

“Together, these powerful complementary forces put us in a more capable and competitive position than ever before to address the commercialization challenges and opportunities of our global clients,” added Weiss.

The 21GRAMS brand, approach and leadership team will operate under W2O’s single, integrated profit and loss (P&L) operation, with access to all of W2O’s proprietary data models and tools as well as it’s 1,000 person strong multidisciplinary team – including data analysts, scientific strategists, branding experts, communications specialists and creatives – to build unfair advantage for clients and their brands. Additionally, the 21GRAMS leadership team will remain the same with Robert Blink, Wendy LevineJayson Dupré and Frank Mazzola.

21GRAMS and W2O are privately held companies and the financial terms of the acquisitions are not being disclosed. A team from Excel Partners, led by Ed Soh and Doug Donohue, served as the exclusive financial advisor to 21GRAMS.

About 21GRAMS

21GRAMS was built to be different by design, fusing advertising and education for the first time in an agency model. As two arms of the same body, these disciplines work seamlessly, to inject creativity into education and give advertising exclusive and personal access to doctors and patients – providing an unmatched ability to uncover deeper insights and create work that truly “gets” them. Using brands people love as a model for connecting with audiences, 21GRAMS adheres to the mantra “Medicine should be more inspiring than sneakers.” Obsessing less on minutia, and more on what makes people tick. For more information, visit 21GRAMSNY.com.

About W2O

Founded by Jim Weiss in 2001, W2O is the leading independent provider of analytics-driven, digital-first marketing and communications to the healthcare sector. W2O applies proprietary analytics models, methodologies and approaches in a digital world to design precise communications and marketing strategies to deliver sustained business results. W2O maintains 15 offices across the United States and in Europe.

For more information, please visit www.w2ogroup.com.

Follow W2O on Twitter
Follow W2O on LinkedIn
Follow W2O on Facebook

Contacts

W2O
Sylvia Aranda, 424-201-9464
saranda@w2ogroup.com

Tags: